Compared side by side
Ipamorelin vs tesamorelin: how they differ
The short answer
They prompt growth hormone release through different receptors: tesamorelin is a GHRH analogue, and ipamorelin a ghrelin receptor agonist that released GH without raising cortisol in animal studies. Tesamorelin is FDA-approved to reduce excess abdominal fat in HIV lipodystrophy, and in two phase 3 trials it cut visceral fat about 15% in 26 weeks; ipamorelin was never approved. Tesamorelin is taken daily, ipamorelin 2–3 times a day.
Side by side
| Compared | Ipamorelin | Tesamorelin |
|---|---|---|
| Category | Growth hormone | Growth hormone |
| Also known as | IPAM | Egrifta |
| What it is | Considered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides. | The only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy). |
| How it works | Selective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available. | Synthetic GHRH analogue FDA-approved for HIV-associated lipodystrophy. Stimulates GH secretion, reduces visceral adiposity, and improves body composition. Its half-life is short, close to sermorelin's (8–11 minutes on the current labels). |
| Commonly reported | Deeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved. | Waist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches. |
| Studied range | Research range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation. | Research range: 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy. |
| How often | 2–3x daily, best fasted or before bed | Daily |
| Half-life | ~2 hours (measured in healthy men, given IV) | ~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min) |
| Route | SubQ injection, IM injection | SubQ injection |
| Typical run | Commonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks. | FDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months. |
| Evidence | Moderate: animal studies + some human data | Established: clinical trials or FDA-approved use exists |
| Common side effects | Headache, flushing, nausea, water retention, numbness/tingling | Injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation |
- Category
- IpamorelinGrowth hormone
- TesamorelinGrowth hormone
- Also known as
- IpamorelinIPAM
- TesamorelinEgrifta
- What it is
- IpamorelinConsidered the 'cleanest' growth hormone stimulator: in animal studies it triggers the pituitary to release GH without raising cortisol, a side effect common with other GH peptides.
- TesamorelinThe only GHRH analog currently FDA-approved (to reduce excess abdominal fat in HIV lipodystrophy).
- How it works
- IpamorelinSelective growth hormone secretagogue and ghrelin receptor agonist. In animal studies it released GH without raising cortisol or ACTH, and users report milder hunger than with GHRP-6. Considered one of the cleanest GH pulses available.
- TesamorelinSynthetic GHRH analogue FDA-approved for HIV-associated lipodystrophy. Stimulates GH secretion, reduces visceral adiposity, and improves body composition. Its half-life is short, close to sermorelin's (8–11 minutes on the current labels).
- Commonly reported
- IpamorelinDeeper sleep and vivid dreams first, then better recovery, skin quality and gradual body-composition changes, with milder hunger than GHRP-6. Its human data are a small GH study and phase 2 trials in surgical patients; it was never approved.
- TesamorelinWaist and belly shrinking while body weight barely moves, with injection-site redness and early joint aches.
- Studied range
- IpamorelinResearch range: 200–300 mcg, starting dose 200 mcg. Studied in research — not a recommendation.
- TesamorelinResearch range: 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.
- How often
- Ipamorelin2–3x daily, best fasted or before bed
- TesamorelinDaily
- Half-life
- Ipamorelin~2 hours (measured in healthy men, given IV)
- Tesamorelin~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min)
- Route
- IpamorelinSubQ injection, IM injection
- TesamorelinSubQ injection
- Typical run
- IpamorelinCommonly 8–12 weeks on, 4 weeks off to avoid receptor desensitisation. Some run longer with breaks.
- TesamorelinFDA approval context: daily use. Community typically runs 12–24 weeks. Reassess at 3 months.
- Evidence
- IpamorelinModerate: animal studies + some human data
- TesamorelinEstablished: clinical trials or FDA-approved use exists
- Common side effects
- IpamorelinHeadache, flushing, nausea, water retention, numbness/tingling
- TesamorelinInjection site reaction, fluid retention, joint pain, nausea, glucose dysregulation
Typical run: Community practice — opinions vary. Not a clinical recommendation.

Week by week
Each entry’s cards by day window, as the compound pages show them. Day 1 is the day you start it.
Ipamorelin
- Day 1–14 Sleep is deepening
- Day 14–28 Recovery is noticeably faster
- Day 28–56 Body composition shifts showing up
- Day 56–84 Cycle-end + planned break
Tesamorelin
- Day 1–14 Targeting the deep belly fat
- Day 14–56 Visceral fat is mobilizing
Together or one or the other
Ipamorelin and tesamorelin are a common stack: tesamorelin lists ipamorelin among its common stacks.
Questions people ask
How long do ipamorelin and tesamorelin last?
The half-life of ipamorelin is ~2 hours (measured in healthy men, given IV). The half-life of tesamorelin is ~8–11 min (current EGRIFTA SV/WR labels; the original label listed ~26 min).
How often are ipamorelin and tesamorelin taken?
Ipamorelin: 2–3x daily, best fasted or before bed. Routes: SubQ injection, IM injection. Tesamorelin: daily. Route: SubQ injection.
How are ipamorelin and tesamorelin dosed in research?
The research range for ipamorelin is 200–300 mcg, with a 200 mcg starting dose. Studied in research — not a recommendation. The research range for tesamorelin is 1–2 mg. Studied in research — not a recommendation. FDA-approved as Egrifta WR (1.28 mg) and Egrifta SV (1.4 mg), SubQ once daily, to reduce excess abdominal fat in adults with HIV lipodystrophy.
What are the common side effects of ipamorelin and tesamorelin?
For ipamorelin, the library lists: headache, flushing, nausea, water retention, numbness/tingling. For tesamorelin: injection site reaction, fluid retention, joint pain, nausea, glucose dysregulation.
Are ipamorelin and tesamorelin taken together?
Ipamorelin and tesamorelin are a common stack: tesamorelin lists ipamorelin among its common stacks.